SRES-464-119
Submitted in the Senate, considered, and agreed to without amendment and with a preamble by Unanimous Consent. (consideration: CR S7735; text: CR S7732-7733)
Sponsored by Cindy Hyde-Smith (R-MS)
What it does
This resolution designates September 2025 as "National Cholesterol Education Month" and September 30, 2025, as "LDL-C Awareness Day." It is a symbolic, non-binding measure that does not appropriate funds, create programs, change regulations, or impose any legal obligations on any person or entity.
Who benefits
Public health organizations and advocacy groups focused on cardiovascular disease may gain visibility and a platform for outreach campaigns. Healthcare providers who treat patients with high cholesterol may benefit from increased public awareness. Pharmaceutical and medical device companies that produce cholesterol-related treatments may see indirect promotional benefit. Patients at risk for cardiovascular disease could benefit if the designation prompts greater awareness and earlier screening.
Who is hurt
No group faces a direct material harm from this resolution. There are no mandates, spending cuts, or regulatory changes. Competing public health awareness causes not recognized in September could be considered indirectly disadvantaged in terms of congressional attention, though this effect is negligible.
Supporters argue
Supporters argue that cardiovascular disease is the leading cause of death in the United States, with high LDL cholesterol being a major modifiable risk factor, and that formal congressional recognition can amplify public health messaging at no cost to taxpayers. They contend that awareness designations have historically been used to coordinate national education campaigns, encouraging Americans to get screened and take preventive action during a focused period.
Opponents argue
Opponents argue that symbolic resolutions consume limited congressional floor time without producing measurable health outcomes, and that the federal government has no evidence that awareness month designations meaningfully change patient behavior or reduce disease rates. They contend that if cholesterol-related illness is a genuine public health priority, Congress should direct resources toward substantive measures — such as funding for screening programs or research — rather than non-binding proclamations.